

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: <b>Margaretha Grind</b>	)	Confirmation No. <b>1056</b>
	)	
Application No. <b>10/550,154</b>	)	Group Art Unit: <b>1654</b>
	)	
Filed: <b>September 20, 2005</b>	)	Examiner: <b>Hemant Khanna, Ph.D.</b>
	)	
For: <b>Use of Low Molecular Weight Thrombin</b>	)	Dated: <b>August 29, 2007</b>
<b>Inhibitors in Cholesterol-Lowering Therapy</b>	)	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or

credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a  
**CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §  
1.136(a)(3).

Dated: **August 29, 2007**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Ave., N.W.  
Washington, D.C. 20004  
Tele: 202-739-3000  
Fax: 202-739-3001

Respectfully submitted  
**Morgan, Lewis & Bockius LLP**

  
\_\_\_\_\_  
Gregory T. Lqwen  
Registration No. 46,882  
Direct: 202-739-5915

<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)  <b>PTO Form 1449</b> (August 29, 2007)				Attorney Docket <b>056291-5256</b>		Application No. <b>10/550,154</b>	
				<b>Page 1 of 1</b>			
				Applicant: <b>Margaretha Grind</b>		Filing Date: <b>September 20, 2005</b>	
				Group Art Unit: <b>1654</b>			

U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
	aa	WO 93/11152	06/10/1993	WIPO			
	ab	WO 97/40024	10/30/1997	WIPO			
	ac	WO 98/37075	08/27/1998	WIPO			
	ad	WO 02/44145 A1	06/06/2002	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	ae	Eriksson et al. (2003) Direct Thrombin Inhibitor Melagatran Followed by Oral Ximelagatran in Comparison With Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Replacement, Thrombosis and Haemostasis, 89(2):288-296, CAS Abstract No. 138:280930
	af	Shinji et al. (1994) Preparation of Aminated Fucoidan and its Evaluation as an Antithrombotic and Antilipemic Agent, Biological & Pharmaceutical Bulletin, 17:784-788, Biosis Abstract No. PREV199497516777
	ag	Szczeklik et al. (1999) Inhibition of Thrombin Generation by Simvastatin and Lack of Additive Effects of Aspirin in Patients With Marked Hypercholesterolemia, J. Am. College of Cardiology, 33(5):1286-1293, Medline Abstract Acc. No. NLM10193729

Examiner	Date Considered
----------	-----------------

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.